Sacubitril/valsartan

Drug Profile

Sacubitril/valsartan

Alternative Names: AHU-377/valsartan; Entresto; LCZ-696; LCZ-696A; Neparvis; Valsartan/AHU-377; Valsartan/sacubitril

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Novartis
  • Class Antihypertensives; Biphenyl compounds; Branched-chain amino acids; Esters; Heart failure therapies; Pentanoic acids; Small molecules; Tetrazoles
  • Mechanism of Action Angiotensin type 1 receptor antagonists; Neprilysin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Heart failure
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Heart failure
  • Phase III Essential hypertension; Hypertension; Kidney disorders

Most Recent Events

  • 18 Mar 2017 Efficacy data from a post-hoc analysis of the phase III PARADIGM-HF trial in Heart failure released by Novartis
  • 08 Mar 2017 Novartis plans a phase III trial for Heart failure (NCT03066804)
  • 01 Mar 2017 Novartis completes the UK HARP-III phase III trial in Kidney disorders (chronic kidney disease) in United Kingdom (ISRCTN11958993)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top